These include CHEK2 mutations in breast cancers and also in a variety of other cancers including thyroid cancer [28], EWSR1 in Ewing sarcoma [29], RET in hereditary medullary thyroid carcinoma, NRP1 in breast cancer [30] and germline POT1 variants in malignant melanoma [31]. This evidence concerns the gene NRP1 and familial medullary thyroid carcinoma.